DCT Contract Funds To Be 20 Percent less In FY 1986 Than In 1985; To Eliminate ‘Low Priority’ Contracts
In Brief: NCI Seeking Industry Support Again For Summer Program Congress Oks Smokeless Tobacco Bill
DCT Board Approves Phase 2/3 Studies Of LAK-IL-2
NCAB Approves Addition Of Two New Organ Systems
Clinical Education Program Phase Out Opposed By NCAB Committee
NCAB Votes To ‘Keep Alive’ Concept For Stage 2 Breast Cancer Fat Trial
Trending Stories
- Spending bill passed by the House gives NIH $415M raise, NCI gets $128M
Legislation caps proportion of NIH grants to receive multiyear funding; indirect costs remain untouched - With five-year cancer survival at an all-time high, does this mean people are living longer?
- Blood Cancer United: A new name at the right moment
- An oncologist navigates terminal sarcoma, insurmountable debt, and “a legacy of grief”
How colleagues and Fargo, ND, neighbors came together to help the Erickson-Abou Zahrs - In The Headlines: Is early detection always good? Inside NCI’s MCD feasibility trial.
- Premarin’s 84-year hold on the market ends as FDA approves a generic version
Trade secret protections helped the hormone drug resist generic entry and outlast safety controversies—including link to cancer









